GlassScriptPhysician profile
William R Procell
NPI 1750342598
$11,317.39
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $1,853 · 2021: $2,747 · 2022: $2,732 · 2023: $2,424 · 2024: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,727.90 | 2020-2024 | |
| Glaxosmithkline, LLC. | $1,629.97 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,068.21 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $858.76 | 2019-2024 | Farxiga, Fasenra, Breztri |
| Lilly USA, LLC | $768.51 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Allergan, INC. | $555.36 | 2019-2020 | |
| Pfizer INC. | $539.22 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $454.83 | 2019-2024 | Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $431.10 | 2021-2023 | Ztlido |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.87 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $360.39 | 2019-2023 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $320.03 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $260.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $222.00 | 2019-2023 | |
| Dexcom, INC. | $220.55 | 2021-2023 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Procell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.